My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
K°benhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 19 (2010) Abstr 1859 [www.page-meeting.org/?abstract=1859]


Poster: Methodology- PBPK


Karina Blei Physiology-based Simulations of Amikacin Pharmacokinetics in Preterm Neonates

K. Claa▀en (1), S. Willmann (2), K. Thelen (3), K. Coboeken (2), K. Allegaert (4), J. Lippert (2)

(1) Radboud University Nijmegen, Organismale Dierfysiologie, 6525 AJ Nijmegen, Netherlands; (2) Bayer Technology Services GmbH, Systems Biology and Computational Solutions, Building E 41, 51368 Leverkusen, Germany; (3) Johann Wolfgang Goethe University Frankfurt, Institute of Pharmaceutical Technology, 60438 Frankfurt am Main, Germany; (4) University Hospitals Leuven, Department of Pediatrics, 3000 Leuven, Belgium

Objectives: This work aimed to extend the database of the physiology-based pharmacokinetic (PBPK) software PK-Sim« to enable simulations in preterm neonates down to 24 weeks of gestational age (GA). The implemented model accounts for both intrauterine development and the postnatal growth and maturation of anatomical and physiological parameters relevant for PBPK modeling.

Methods: Information about physiological parameters of neonates born between 24 and 40 weeks of gestation have been collected from the literature and implemented into the database of PK-Sim«. The aminoglycoside antibiotic amikacin was chosen as a model drug based on the availability of a previously established amikacin model for adults and therapeutic drug monitoring (TDM) data in preterms reported by Allegaert et al [1], [2]. Plasma concentration time curves after a single intravenous dose of amikacin were simulated in virtual populations and compared to the experimental data obtained in neonates with a maximum postnatal age of 6 days.

Results: Simulation results of amikacin pharmacokinetics demonstrate a reasonable representation of TDM data in preterm neonates. Most data points fall within the 5th to 95th percentile of the simulated populations. Only a slight possible bias to lower predicted concentrations is observed.

Conclusions: A physiology-based model to simulate pharmacokinetics in preterm neonates has been developed and implemented in PK-Sim«. A comparison of simulated amikacin plasma concentrations with in vivo TDM data demonstrates the predictive capabilities of the preterm PBPK model.

References:
[1] Allegaert, K., Cossey, V., Langhendries, J.P., Naulaers, G., Vanhole, C. et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 86, 207-211 (2004).
[2] Allegaert, K., Scheers, I., Cossey, V. & Anderson, B.J. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett 2, 286-289 (2008).